Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of the stock in a transaction dated Thursday, January 10th. The shares were sold at an average price of $34.55, for a total value of $269,490.00. Following the completion of the sale, the chief executive officer now owns 733,285 shares of the company’s stock, valued at $25,334,996.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NASDAQ:ATRA opened at $35.01 on Friday. Atara Biotherapeutics Inc has a 52-week low of $22.15 and a 52-week high of $54.45. The stock has a market capitalization of $1.55 billion, a PE ratio of -8.75 and a beta of 2.47.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.16). As a group, research analysts anticipate that Atara Biotherapeutics Inc will post -4.82 EPS for the current year.
A number of equities research analysts have commented on ATRA shares. BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 12th. Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, November 30th. Finally, Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 31st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Atara Biotherapeutics has an average rating of “Hold” and an average price target of $47.80.
COPYRIGHT VIOLATION WARNING: “Isaac E. Ciechanover Sells 7,800 Shares of Atara Biotherapeutics Inc (ATRA) Stock” was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.themarketsdaily.com/2019/01/12/isaac-e-ciechanover-sells-7800-shares-of-atara-biotherapeutics-inc-atra-stock.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: How to Invest in a Bull Market
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.